Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes

American Journal of Cardiology

Volumn 105, Issue 6, 2010, Pages 833-838

  Gaglia Jr , Michael A ^a   Torguson, Rebecca ^a   Hanna, Nicholas ^a   Gonzalez, Manuel A ^a   Collins, Sara D ^a   Syed, Asmir I ^a   Ben Dor, Itsik ^a   Maluenda, Gabriel ^a   Delhaye, Cedric ^a   Wakabayashi, Kohei ^a   Xue, Zhenyi ^a   Suddath, William O ^a   Kent, Kenneth M ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; SURVIVAL RATE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; DRUG-ELUTING STENTS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; SURVIVAL RATE; TICLOPIDINE;

EID: 77649183199     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.063     Document Type: Article

References (31)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., and Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., Jacobs A.K., Morrison D.A., Williams D.O., Feldman T.E., Kern M.J., O'Neill W.W., Schaff H.V., Whitlow P.L., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., Ettinger S.M., Halperin J.L., Hunt S.A., Krumholz H.M., Kushner F.G., Lytle B.W., Nishimura R., Page R.L., Riegel B., Tarkington L.G., and Yancy C.W. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 51 (2008) 172-209
4. Hallas J., Dall M., Andries A., Andersen B.S., Aalykke C., Hansen J.M., Andersen M., and Lassen A.T. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 (2006) 726
5. Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K., Furberg C.D., Johnson D.A., Mahaffey K.W., and Quigley E.M. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118 (2008) 1894-1909
6. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., and Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
7. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., Mansourati J., Mottier D., Abgrall J.F., and Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
8. Cuisset T., Frere C., Quilici J., Poyet R., Gaborit B., Bali L., Brissy O., Morange P.E., Alessi M.C., and Bonnet J.L. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54 (2009) 1149-1153
9. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., and Costa M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
10. Li X.Q., Andersson T.B., Ahlstrom M., and Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 821-827
11. Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest II C.S., Lachno D.R., Salazar D., and Winters K.J. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
12. Ishizaki T., and Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl 3 (1999) 27-36
13. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., and Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
14. Frere C., Cuisset T., Morange P.E., Quilici J., Camoin-Jau L., Saut N., Faille D., Lambert M., Juhan-Vague I., Bonnet J.L., and Alessi M.C. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101 (2008) 1088-1093
15. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., and Sabatine M.S. Cytochrome p450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
16. Kim K.A., Park P.W., Hong S.J., and Park J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84 (2008) 236-242
17. Juurlink D.N., Gomes T., Ko D.T., Szmitko P.E., Austin P.C., Tu J.V., Henry D.A., Kopp A., and Mamdani M.M. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 180 (2009) 713-718
18. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., and Rumsfeld J.S. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
19. Stanek EJ, Aubert RE, Flockhart DA, Kreutz RP, Yao Y, Breall JA, Desta Z, Skaar TC, Frueh FW, Teagarden JR, Epstein RS. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes study. Abstract presented at the Society for Cardiovascular Angiography and Interventions, May 6, 2009.
20. Bhatt DL, Cryer B, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Scirica BM, Giugliano RP, Cannon CP; COGENT Investigators. Clopidogrel and the Optimization of GI Events Trial. Abstract presented at Transcatheter Cardiovascular Therapeutics, September 24, 2009.
21. Blume H., Donath F., Warnke A., and Schug B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29 (2006) 769-784
22. Meyer U.A. Interaction of proton pump inhibitors with cytochrome P450: consequences for drug interactions. Yale J Biol Med 69 (1996) 203-209
23. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., Schomig A., Kastrati A., and von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101 (2009) 714-719
24. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., and Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 (2009) 148e 1-5
25. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., Bujanda L., Gomollon F., Forne M., Aleman S., Nicolas D., Feu F., Gonzalez-Perez A., Borda A., Castro M., Poveda M.J., and Arenas J. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
26. Lai K.C., Lam S.K., Chu K.M., Wong B.C., Hui W.M., Hu W.H., Lau G.K., Wong W.M., Yuen M.F., Chan A.O., Lai C.L., and Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
27. Cryer B., Jermano J., Lanza F., Miner P., Schwartz H., Azarnoff D., and Goldsmith M. Omeprazole can prevent the gastroduodenal mucosal injury associated with combined use of clopidogrel and aspirin. Am J Gastroenterol 103 Suppl 1 (2008) S49
28. Ng F.H., Wong S.Y., Lam K.F., Chang C.M., Lau Y.K., Chu W.M., and Wong B.C. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 103 (2008) 865-871
29. Barada K., Karrowni W., Abdallah M., Shamseddeen W., Sharara A.I., and Dakik H.A. Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors. J Clin Gastroenterol 42 (2008) 368-372
30. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am 38 (2009) 289-303
31. Food and Drug Administration. Follow-up to the January 26, 2009 early communication about an ongoing safety review of clopidogrel bisulfate (marketed as plavix) and omeprazole (marketed as prilosec and prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm Accessed on November 23, 2009